NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lai Kai Pharmaceutical Technology

Lai Kai Pharmaceutical Technology

Public
Shanghai, ShanghaiBiotechwww.laeknatp.com

Lai Kai Pharmaceutical Technology is now publicly traded

The data on this page reflects Lai Kai Pharmaceutical Technology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Jun 29, 2023

Last Round

Private Placement

Sep 24, 2025

Total Funding Raised

$344.31M

Company Overview

Laekna Therapeutics (HKG: 02105) is a biotechnology company focused on developing innovative therapies for cancer treatment through a robust R&D infrastructure and multiple clinical trials.

Sector

Biotech

AI Layer

Non-AI

Keywords

oral pan-AKT inhibitor for cancerclinical-stage cancer therapiescombination therapy for drug-resistant cancermetabolic disease drug developmentdrug candidate pipeline developmentbiotech drug in-licensingpharmaceutical co-development partnershipActRIIA antibody for obesitysmall molecule drug candidatesantibody-based therapeuticsCYP17A1/CYP11B2 inhibitor for prostate cancertherapies for solid tumorsanti-PD-L1 antibodyliver fibrosis therapies

Lai Kai Pharmaceutical Technology Comparables

Compare Lai Kai Pharmaceutical Technology with similar companies based on industry and business-model similarity.

Lai Kai Pharmaceutical Technology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Lai Kai Pharmaceutical Technology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private PlacementSep 24, 2025
IPOJun 29, 2023
Series DMay 18, 2022
Series COct 1, 2020
Series BApr 2, 2019
Series A
Jun 4, 2018

Lai Kai Pharmaceutical Technology Investors

Notable investors and investment history

Lai Kai Pharmaceutical Technology investors
InvestorRounds
OrbiMed AsiaSeries B, Series A
Yanchuang CapitalSeries D
CS CapitalIPO, Series C, Series D
Ningbo Yaoshang Yanchuang Chenkai Venture Capital Partnership (Limited Partnership)IPO
SDIC Innovation Investment ManagementIPO
OrbiMedSeries B, Series A, IPO
Infinity CapitalSeries D

Lai Kai Pharmaceutical Technology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lai Kai Pharmaceutical Technology Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersShanghai, Shanghai
Year Founded2016
Last FundingSep 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.